Comparison of Combined Nebulization of Salbutamol-Ipratropium Bromide with Salbutamol Alone in Children with Mild and Moderate Acute Asthma
ntroduction: The β2 agonists are potent bronchodilators but their repeated and high doses are related to adrenergic side effects. While ipratropium bromide, an anticholinergic bronchodilator has less adverse effects.
Objective: To compare the efficacy of combined nebulization of salbutamol-ipratropium bromide with salbutamol alone in children with mild and moderate acute asthma.
Materials and Methods: This randomised control trial was done on 80 children aged 5 to 12 years who presented with mild to moderate acute asthma in the emergency department of Children Hospital of Pakistan Institute of Medical Sciences (PIMS) from July 2014 to June 2016 and randomized into 2 groups. In the experimental group each child received 2 nebulizations of combined salbutamol (5mg) and ipratropium Bromide (0.25mg) at presentation and 20 minutes later. Similarly, each child of the control group received 2 nebulizations of 5mg Salbutamol and 2 ml of Normal saline. Asthma clinical score (ACS) was assessed at baseline and then after every 20 minutes up to one hour after the presentation.
Results: In the experimental group, the mean + SD ACS at presentation and 60 minutes were 3.50±1.8 and 3.45±1.7 respectively with mean + SD change in ACS of 0.05 ± 0.1. In the control group, the mean + SD ACS at presentation and 60 minutes were 3.70 ± 1.2 and 3.60 ± 1.9, respectively with mean + SD change in ACS of 0.1 ± 0.7. This difference in mean + SD change in ACS between 2 groups was not statistically significant (P=0.6560).
Conclusion: There is no statistically significant benefit of adding ipratropium bromide with salbutamol nebulization as compared to salbutamol alone for the management of children with mild to moderate asthma attacks.
2. Conner JB, Buck PO. Improving Asthma Management: The Case for Mandatory Inclusion of Dose Counters on All Rescue Bronchodilators. J Asthma [Internet]. 2013;50(6):658–63. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741013/pdf/JAS-50-658.pdf
3. Ahmed N, Lehrasab W, Bibi R. Morbidity Patterns in Asthmatic Children Presenting to A Tertiary Care Setting. Ann Pak Inst Med Sci [Internet]. 2015;11(2):100=104. Available from: https://apims.net/apims_old/Volumes/Vol11-2/Morbidity Patterns in Asthmatic Children Presenting to Tertiary Care Hospital.pdf
4. Iqbal ZH, Saleem A. A local experience of bronchial asthma. J Allama Iqbal Med Coll [Internet]. 2009;7(4):64–64. Available from: http://www.pakmedinet.com/14952
5. Afzal M, Qureshi SM, Hussain S, Tariq NA. Risk factors associated with childhood asthma among children aged 1-12 years in Rawalpindi. Pak Armed Forces Med J [Internet]. 2011;61(3):372-6. Available from: http://www.pafmj.org/index.php/PAFMJ/article/view/745/604
6. Majeed R, Rajar UDM, Shaikh N, Majeed F, Arain AA. Risk Factors Associated with Childhood Asthma. J Coll Physicians Surg Pakistan [Internet]. 2008;18(5):299–302. Available from: https://jcpsp.pk/archive/2008/May2008/10.pdf
7. Khan AA, Tanzil S, Jamali T, Shahid A, Naeem S, Sahito A, et al. Burden of asthma among children in a developing megacity: childhood asthma study, Pakistan. J Asthma [Internet]. 2014 Nov 3;51(9):891–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24894743
8. Addo-Yobo, Emmanuelk O, Ade S, Agodokpess G, Aguirre V. The Global Asthma Report [Internet]. Global Asthma Network; 2018. 89 p. Available from: www.globalasthmanetwork.org
9. Ortiz-Alvarez O, Mikrogianakis A. Managing the paediatric patient with an acute asthma exacerbation. Paediatr Child Health [Internet]. 2012;17(5):251. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381918/
10. Jones PW. Assessment and management of asthma and COPD - converging approaches. J Postgr Med Inst [Internet]. 2011;25(4):280–5. Available from: http://www.pakmedinet.com/17579
11. Galanter JM, Boushey HA. Drugs used in Asthma. In: Katzung BG, Weitz M, Boyle P, editors. Basic & Clnical Pharmacology [Internet]. 14th ed. San Francisco: McGraw-Hill; 2018. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2249§ionid=175215158
12. Iramain R, López-Herce J, Coronel J, Spitters C, Guggiari J, Bogado N. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma [Internet]. 2011 Apr;48(3):298–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21332430
13. Zorc JJ, Pusic M V., Ogborn CJ, Lebet R, Duggan AK. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics. 1999 Apr;103(4 I):748–52.
14. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-analysis. Vol. 60, Thorax. BMJ Publishing Group; 2005. p. 740–6.
15. Kirkland SW, Vandenberghe C, Voaklander B, Nikel T, Campbell S, Rowe BH. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Vol. 2017, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2017.
16. Sharma A, Madaan A. Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian J Pediatr [Internet]. 2004 Feb;71(2):121–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15053373
17. Rayner RJ, Cartlidge HT, Upton CJ. Salbutamol and ipratropium in acute asthma. Arch Dis Child [Internet]. 1987;62(8):840–1. Available from: https://adc.bmj.com/content/archdischild/62/8/840.full.pdf
18. Memon BN, Parkash A, Khalid Mahmood, Ahmed Khan. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. J Pak Med Assoc [Internet]. 2016;66(3):243–6. Available from: https://jpma.org.pk/PdfDownload/7648
19. Khan A, Ahmad M. Comparison of Salbutamol Alone With Salbutamol Plus Ipratropium Bromide in the Treatment of Acute Asthma in Children. Khyber J Med Sci [Internet]. 2016;9(3):391–4. Available from: http://kjms.com.pk/sites/default/files/KJMS 25_1.pdf
20. Ducharme FM, Chalut D, Plotnick L, Savdie C, Kudirka D, Zhang X, et al. The Pediatric Respiratory Assessment Measure: A Valid Clinical Score for Assessing Acute Asthma Severity from Toddlers to Teenagers. J Pediatr [Internet]. 2008 Apr;152(4):476-480.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18346499
21. Chalut D, Ducharme F, Davis G. AHS Acute Childhood Asthma Pathway: Evidence based recommendations [Internet]. 2012. Available from: http://pert.ucalgary.ca/airways/AHS Asthma ED_UCC algorithm document (v7)_2012Aug09.pdf
22. Harumdini M, Supriyatno B, Sekartini R. Efficacy of salbutamol-ipratropium bromide nebulization compared to salbutamol alone in children with mild to moderate asthma attacks. Paediatr Indones [Internet]. 2012;52(4):200–8. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/397/281
23. Birken CS, Parkin PC, Macarthur C. Asthma severity scores for preschoolers displayed weaknesses in reliability, validity, and responsiveness. J Clin Epidemiol [Internet]. 2004 Nov [cited 2020 Jul 9];57(11):1177–81. Available from: https://pubmed.ncbi.nlm.nih.gov/15567635/
24. Belgrave DCM, Simpson A, Semic-Jusufagic A, Murray CS, Buchan I, Pickles A, et al. Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing. J Allergy Clin Immunol [Internet]. 2013 [cited 2020 Jul 9];132(3). Available from: https://pubmed.ncbi.nlm.nih.gov/23906378/
25. Wyatt EL, Borland ML, Doyle SK, Geelhoed GC. Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial. J Paediatr Child Health [Internet]. 2015 Feb;51(2):192–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25039574
26. Kumaratne M, Gunawardane G. Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office. Clin Pediatr (Phila) [Internet]. 2003 Mar 2;42(2):127–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12659385
27. Craven D, Kercsmar CM, Myers TR, O’Riordan MA, Golonka G, Moore S. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr [Internet]. 2001 Jan;138(1):51–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11148512
28. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta 2 -agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev [Internet]. 2014 Jul 31; Available from: http://doi.wiley.com/10.1002/14651858.CD010283.pub2
29. Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, et al. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: A randomized controlled trial. BMC Pulm Med. 2016;16(1).
30. Chakraborti A, Lodha R, Pandey RM, Kabra SK. Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian J Pediatr [Internet]. 2006 Nov;73(11):979–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17127777
31. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta 2 -agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev [Internet]. 2013 Aug 21;(8):CD000060. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/epdf/abstract
32. Castro-Rodriguez JA, Rodrigo GJ, Rodríguez-Martínez CE. Principal findings of systematic reviews of acute asthma treatment in childhood. Vol. 52, Journal of Asthma. Taylor and Francis Ltd; 2015. p. 1038–45.
Copyright (c) 2020 Naima Fazil Raja, Asmat Perveen, Imran Mahmood Khan, Maqbool Hussain, Jai Krishin, Sajid Hussain Sherazi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.